Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Liabilities and Shareholders Equity (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $167.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 94.89% to $167.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $652.2 million, a 51.38% increase, with the full-year FY2024 number at $70.3 million, down 46.9% from a year prior.
  • Liabilities and Shareholders Equity was $167.0 million for Q3 2025 at Whitehawk Therapeutics, down from $180.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $234.0 million in Q1 2025 to a low of $37.4 million in Q2 2021.
  • A 5-year average of $136.8 million and a median of $142.3 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 245.76% in 2022, then tumbled 46.9% in 2024.
  • Whitehawk Therapeutics' Liabilities and Shareholders Equity stood at $157.9 million in 2021, then increased by 16.67% to $184.2 million in 2022, then fell by 28.12% to $132.4 million in 2023, then crashed by 46.9% to $70.3 million in 2024, then surged by 137.51% to $167.0 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Liabilities and Shareholders Equity are $167.0 million (Q3 2025), $180.8 million (Q2 2025), and $234.0 million (Q1 2025).